SCHEMBL16450366

SCHEMBL16450366

CCCCC[n+]1ccc(C)c2ccccc21

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.57
HTT P42858 6/20 0.57
SMN1; SMN2 Q16637 6/20 0.57
NPC1 O15118 5/20 0.57
RAB9A P51151 5/20 0.57
ALDH1A1 P00352 4/20 0.57
GAA P10253 4/20 0.57
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
POLB P06746 1/20 0.57
GLA P06280 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
RCE1 Q9Y256 1/20 0.57
NPSR1 Q6W5P4 3/20 0.56
LMNA P02545 2/20 0.56
MAPK1 P28482 2/20 0.56
RAD52 P43351 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2D6 P10635 1/20 0.56
HPGD P15428 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12201165 0.98 KDM4E (0.58) KDM4EHTTSMN1; SMN2NPC1RAB9A
SCHEMBL26662987 0.98 KDM4E (0.58) KDM4EHTTSMN1; SMN2NPC1RAB9A
SCHEMBL12201171 0.98 KDM4E (0.58) KDM4EHTTSMN1; SMN2NPC1RAB9A
Bromide SCHEMBL10439579 0.97 KDM4E (0.61) KDM4EHTTSMN1; SMN2NPC1RAB9A
Iodide SCHEMBL9292447 0.97 KDM4E (0.61) KDM4EHTTSMN1; SMN2NPC1RAB9A
SCHEMBL12201138 0.95 KDM4E (0.59) KDM4EHTTSMN1; SMN2NPC1RAB9A
SCHEMBL13645489 0.93 KDM4E (0.64) KDM4EHTTSMN1; SMN2POLBRECQL
SCHEMBL13686278 0.91 KDM4E (0.62) KDM4EPOLBRECQLBCHEACHE
SCHEMBL12201164 0.88 KDM4E (0.62) KDM4EHTTSMN1; SMN2NPC1RAB9A
SCHEMBL11579424 0.83 KDM4E (0.51) KDM4EHTTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150044143-A1 FLUORESCENT MEMBRANE INTERCALATING PROBES AND METHODS FOR THEIR USE PHANOS TECHNOLOGIES, INC. (US) 2015-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150044143-A1 FLUORESCENT MEMBRANE INTERCALATING PROBES AND METHODS FOR THEIR USE TIMM44, SLC47A2, TIMM50 KDM4E 4493/4885HTT 4328/4885SMN1; SMN2 4592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.